Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 3Neoplasms 1Hormone-Refractory Prostate Cancer 1Adenocarcinoma of the Prostate 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has results × sipuleucel-T × Clear all
NCT03686683 2024-10-08

ProVent

Dendreon

Phase 3 Completed
532 enrolled 14 charts
Genitourinary

Adenocarcinoma of the Prostate

NCT00779402 2018-01-29

PROTECT

Dendreon

Phase 3 Completed
176 enrolled 14 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00005947 2010-11-01

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Dendreon

Phase 3 Completed
127 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01133704 2010-09-08

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Dendreon

Phase 3 Completed
98 enrolled 9 charts
Genitourinary

Hormone-Refractory Prostate Cancer

NCT00065442 2010-09-06

ProvengeĀ® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Dendreon

Phase 3 Completed
512 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔